Novel avenues for treating diabetic nephropathy: new investigational drugs.

about

Antioxidant agents for delaying diabetic kidney disease progression: A systematic review and meta-analysis.Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease.

P2860

Q33751985-6DBB5AB1-A3A2-4844-8299-2AA6396A85F1 Q47243282-6A9AD117-1EB7-4FBD-973D-0218CAE0D70D

P2860

Novel avenues for treating diabetic nephropathy: new investigational drugs.

Item

http://www.wikidata.org/entity/Q39170387

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Novel avenues for treating diabetic nephropathy: new investigational drugs.

@en

Novel avenues for treating diabetic nephropathy: new investigational drugs.

@nl

type

Item

label

Novel avenues for treating diabetic nephropathy: new investigational drugs.

@en

Novel avenues for treating diabetic nephropathy: new investigational drugs.

@nl

prefLabel

Novel avenues for treating diabetic nephropathy: new investigational drugs.

@en

Novel avenues for treating diabetic nephropathy: new investigational drugs.

@nl

P1476

Novel avenues for treating diabetic nephropathy: new investigational drugs

@en

P2093

Carmen Ferrajolo

http://www.w3.org/2001/XMLSchema#string

Giovanni Conti

http://www.w3.org/2001/XMLSchema#string

Luca Visconti

http://www.w3.org/2001/XMLSchema#string

Michele Buemi

http://www.w3.org/2001/XMLSchema#string

Valeria Cernaro

http://www.w3.org/2001/XMLSchema#string

Vincenzo Pellicanò

http://www.w3.org/2001/XMLSchema#string

Viviana Lacava

http://www.w3.org/2001/XMLSchema#string

P2860

Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress

New insights on the role of vitamin D in the progression of renal damage

The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

Safety issues and prospects for future generations of PPAR modulators

Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats

Alterations of vitronectin and its receptor alpha(v) integrin in the rat renal glomerular wall during diabetes

Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria

Potential new therapeutic agents for diabetic kidney disease.

Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion.

P304

445-462

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13543784.2017.1293039

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Domenico Santoro

P577

2017-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28277032

http://www.w3.org/2001/XMLSchema#string

Novel avenues for treating diabetic nephropathy: new investigational drugs.

about

P2860

P2860

Novel avenues for treating diabetic nephropathy: new investigational drugs.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698